# Pizarra — PT-pseudo_b9aa0df93f2a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9aa0df93f2a
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 5.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 1.47 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8111057 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.

Vitals: weight 116 kg, height 175 cm, BMI 37.9, BP 149/83 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result.

History: A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent.

Physical examination: Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent.

Patient info: warehouse manager; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.51 +/- 0.19   (95% CI 0.14-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.9 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=5.5, age=71.0, psad=0.12, dre_ord=0.0, vol=49.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS=5.0, PSA=5.5, Age=71, PSA Density=0.12, DRE=Normal, Volume=49.0 mL, Prior Biopsy=Positive) and could not account for the clinical context, such as the patient's moderate LUTS (IPSS=15), the specific PSA velocity (1.47 ng/mL/yr), or the clinical significance of the prior positive biopsy result in the context of the current high-risk imaging.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 51% probability, which falls into the 'discuss' tier ($\pm 0.19$ error bar straddles 0.5). This suggests the classifier is genuinely uncertain. This uncertainty could be misleading because the prior failed to weigh the high PI-RADS 5 score against the prior positive biopsy result, potentially leading to an inappropriate recommendation. Furthermore, the prior did not account for the guideline criterion that the decision hinges on retrieved documents, which is a critical omission.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

Retrieving the radiology report would clarify if the PI-RADS 5 lesion is stable or has changed, which directly impacts the need for a repeat biopsy.

GUIDELINE ANCHOR
The guideline search indicates that the decision is dependent on whether the prior grade is documented and whether the lesion has changed against a previous MRI, as the panel alone cannot settle the case.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_b9aa0df93f2a", "radiology_report": "Subject: mpMRI Prostate | Institution: LUMC, Leiden | Date: 28 January 2025\n\nIndication: Assessment of escalating prostate-specific antigen (5.5 ng/mL) alongside a prior positive biopsy result.\n\nFINDINGS:\nThe gland measures 49.0 mL in volume and exhibits subtle asymmetry. A discrete, approximately 12 mm focus is noted within the left peripheral zone at the mid-gland level. T2-weighted sequences show marked hypointensity. Diffusion-weighted imaging confirms restricted diffusion with correspondingly reduced apparent diffusion coefficient values. Dynamic contrast-enhanced sequences display early, focal enhancement compared to adjacent tissue. No extraprostatic extension, seminal vesicle invasion, or suspicious lymphadenopathy is present.\n\nIMPRESSION:\nPI-RADS 5 lesion in the left mid peripheral zone. PSAD 0.12 ng/mL/mL. csPCa predicted probability 0.8111057"}
get_psa_trend
{"case_id": "PT-pseudo_b9aa0df93f2a", "psa_trend": [{"date": "Aug 2023", "val": 1.5}, {"date": "May 2024", "val": 1.2}, {"date": "Feb 2025", "val": 5.5}]}
get_previous_notes
{"case_id": "PT-pseudo_b9aa0df93f2a", "previous_notes": [{"date": "10 Feb 2024", "author": "Dr. F. de Boer (GP)", "text": "Review of escalating prostate-specific antigen values, which climbed from 2.5 ng/mL in August 2023. Because of the prior positive biopsy and the upward trend, a referral to the urology outpatient clinic was scheduled for further evaluation and imaging."}]}
get_lab_results
{"case_id": "PT-pseudo_b9aa0df93f2a", "laboratory_results": [{"name": "PSA", "val": "5.5 ng/mL", "date": "18 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.05 ng/mL", "date": "18 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "19%", "date": "18 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "14.6 g/dL", "date": "18 Jan 2025", "flag": ""}, {"name": "WBC", "val": "5.7 x10^9/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "227 x10^9/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "78 umol/L", "date": "18 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "18 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "9.3 nmol/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "41 U/L", "date": "18 Jan 2025", "flag": ""}, {"name": "LDH", "val": "122 U/L", "date": "18 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "5.8 %", "date": "18 Jan 2025", "flag": ""}]}

NOT RETRIEVED
The specific ISUP grade group or Gleason score of the prior biopsy result was not documented in the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion in the left mid peripheral zone, 12 mm size, with restricted diffusion and focal enhancement.
- PSA trend: Rising from 1.2 ng/mL (May 2024) to 5.5 ng/mL (Feb 2025).
- Previous notes: Referral was made due to escalating PSA and prior positive biopsy.

AGAINST sampling this patient now:
- Previous notes: Patient is on a re-evaluation pathway, and the decision hinges on whether the prior grade is documented.

WHERE THIS LEANS
The evidence strongly suggests sampling is warranted due to the high-risk PI-RADS 5 finding and the rising PSA velocity, which aligns with the statistical prior's suggestion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: uncertain)

Although the patient has a prior positive biopsy, the decision hinges on whether the prior grade is documented, which it is not. The retrieved evidence shows a high-risk PI-RADS 5 lesion and a rising PSA trend from 1.2 ng/mL to 5.5 ng/mL, which strongly supports sampling. Since no retrieved document confirms a definitive staging pathway or a documented prior grade, proceeding with biopsy is warranted to determine the current status of the lesion.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
